Patents by Inventor Chiang J. Li

Chiang J. Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180250260
    Abstract: Methods comprising administration of, and kits comprising, at least one compound of formula (I) FOLFIRI, and optionally at least one angiogenesis inhibitor.
    Type: Application
    Filed: April 18, 2016
    Publication date: September 6, 2018
    Applicant: BOSTON BIOMEDICAL., INC.
    Inventors: Chiang J LI, Wei LI, Youzhi LI, Laura BORODYANSKY, Yuan GAO, David P. KERSTEIN
  • Publication number: 20180250261
    Abstract: Methods comprising administering and kits comprising at least one compound of formula A: (A) prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing, and at least one compound of formula B: (B) prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.
    Type: Application
    Filed: April 26, 2016
    Publication date: September 6, 2018
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang J. LI, Youzhi LI, Harry ROGOFF, Yuan GAO, Janet HUANG
  • Patent number: 10017488
    Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 10, 2018
    Assignee: Boston Biomedical, Inc.
    Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang J. Li, Wei Li, David Leggett
  • Publication number: 20180140572
    Abstract: Disclosed herein are methods for use in treating cancer comprising administering at least one cancer sternness inhibitor, for example, at least one STAT3 pathway inhibitor such as 2-acetylnaphtho [2, 3-b] furan-4, 9-dione, in order to sensitize or re-sensitive a cancer that is naive, resistant, or/and refractory to at least one immunotherapeutic agent, such as at least one immune checkpoint modulator.
    Type: Application
    Filed: June 3, 2016
    Publication date: May 24, 2018
    Inventors: Chiang J. Li, Youzhi Li, Yuan Gao, Yuxin Wang, Janet Huang, Harry Rogoff
  • Publication number: 20180098959
    Abstract: Methods comprising administration of and kits comprising at least one compound of formula (I); and at least one additional anti-cancer therapy chosen from panitumumab, cetuximab, capecitabine, CAPDX, regorafenib, and FOLFOX.
    Type: Application
    Filed: April 18, 2016
    Publication date: April 12, 2018
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang J. LI, Youzhi LI, Laura BORODYANSKY, Yuan GAO, David LEGGETT, David P. KERSTEIN
  • Publication number: 20180085341
    Abstract: Methods comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I).
    Type: Application
    Filed: April 18, 2016
    Publication date: March 29, 2018
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang J. LI, Wei LI, Youzhi LI, Matthew J. Hitron, Yuan GAO
  • Publication number: 20180087060
    Abstract: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
    Type: Application
    Filed: December 9, 2017
    Publication date: March 29, 2018
    Inventors: Johannes H. Fruehauf, Chiang J. Li
  • Publication number: 20170362299
    Abstract: Novel synthetic biology-based ADCC technologies are provided that enhance or enable ADCC responses, for example, through a rationally-designed soluble universal ADCC enhancer protein (SUAEP) where a high-affinity CD3-binding domain is fused to a high-affinity Fc-binding domain. The SUAEP technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
    Type: Application
    Filed: December 8, 2015
    Publication date: December 21, 2017
    Inventors: CHIANG J. LI, SHYAM UNNIRAMAN
  • Publication number: 20170174646
    Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 22, 2017
    Applicant: Boston Biomedical, Inc.
    Inventors: Toshihiko SONE, Wataru HIROSE, Naoaki SHIMADA, Chiang J. LI, Wei LI, David LEGGETT
  • Publication number: 20160355566
    Abstract: A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
    Type: Application
    Filed: January 8, 2015
    Publication date: December 8, 2016
    Inventors: CHIANG J. LI, SHYAM UNNIRAMAN
  • Publication number: 20160355515
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi Moussa, Neru Munshi
  • Patent number: 9481884
    Abstract: The present invention provides a method of enabling the use of long dsRNA for gene silencing in mammalian cells through bacteria, preferably non-pathogenic or therapeutic strains of bacteria. DNA that encodes long double-strand RNAs are transformed into bacteria and processed in the bacterial cells into a mixture of smaller RNA duplexes and then released into the cytoplasm of the target cells, resulting in modulation of gene expression in the target cells. The methods overcome the incompatibility between long strong dsRNA and mammalian cells by eliminating, or mitigating, the non-specific innate immune response. The eukaryotic cells can be mammalian cells or avian cells. The gene of interest can be a mammalian, avian, bacterial, eukaryotic, or viral gene.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: November 1, 2016
    Assignee: 1GLOBE BIOMEDICAL CO., LTD.
    Inventor: Chiang J. Li
  • Patent number: 9447088
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 20, 2016
    Assignee: ArQule, Inc.
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi Moussa, Neru Munshi
  • Publication number: 20150017138
    Abstract: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Johannes H. Fruehauf, Chiang J. Li
  • Publication number: 20140200199
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi Moussa, Neru Munshi
  • Patent number: 8754078
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 17, 2014
    Assignee: ArQule, Inc.
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, Neru Munshi
  • Publication number: 20130330824
    Abstract: The present invention provides a method of enabling the use of long dsRNA for gene silencing in mammalian cells through bacteria, preferably non-pathogenic or therapeutic strains of bacteria. DNA that encodes long double-strand RNAs are transformed into bacteria and processed in the bacterial cells into a mixture of smaller RNA duplexes and then released into the cytoplasm of the target cells, resulting in modulation of gene expression in the target cells. The methods overcome the incompatibility between long strong dsRNA and mammalian cells by eliminating, or mitigating, the non-specific innate immune response. The eukaryotic cells can be mammalian cells or avian cells. The gene of interest can be a mammalian, avian, bacterial, eukaryotic, or viral gene.
    Type: Application
    Filed: July 25, 2013
    Publication date: December 12, 2013
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventor: CHIANG J. LI
  • Patent number: 8377927
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: February 19, 2013
    Assignee: ArQule, Inc.
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, Neru Munshi
  • Publication number: 20120009153
    Abstract: The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of Salmonella bacteria containing nucleic acid expression constructs encoding shRNAs. In this process, shRNA expressed by the Salmonella silences or knocks down genes of interest (target genes) inside target cells. The nucleic acid expression constructs of the invention include an RNA polymerase (e.g., a T7 polymerase), an RNA polymerase promoter (e.g., a T7 polymerase promoter), and an RNA polymerase terminator (e.g., a T7 polymerase terminator). The Salmonella bacteria can also include, on the same or different nucleic acid construct, an endosomal release factor (e.g., HlyA).
    Type: Application
    Filed: August 13, 2010
    Publication date: January 12, 2012
    Inventors: Hongnian Guo, Chiang J. Li, Johannes Fruehauf
  • Patent number: 8067459
    Abstract: The invention provides lapachone analogs and derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of cancer or precancerous conditions.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: November 29, 2011
    Assignee: ArQule, Inc.
    Inventors: Mark Ashwell, Manish Tandon, Jean-Marc Lapierre, Syed Ali, Yanbin Liu, Chiang J. Li